Salute e Benessere
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program involves DCVax -L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax -Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania .
Dave Innes
804-513-6758
dinnes@nwbio.com
Les Goldman
240-234-0059
lgoldman@nwbio.com
Logo - https://mma.prnewswire.com/media/325355/5365652/northwest_biotherapeutics__inc__logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/northwest-biotherapeutics-announces-upcoming-presentation-on-next-generation-dendritic-cells-for-enhanced-anti-tumor-treatments-302479291.html